Interaction of Antifungal Drugs with CYP3A- and OATP1B-Mediated Venetoclax Elimination

• Main Authors: Eric D. Eisenmann (Author), Dominique A. Garrison (Author), Zahra Talebi (Author), Yan Jin (Author), Josie A. Silvaroli (Author), Jin-Gyu Kim (Author), Alex Sparreboom (Author), Michael R. Savona (Author), Alice S. Mims (Author), Sharyn D. Baker (Author)
• Format: Book
• Published: MDPI AG, 2022-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Venetoclax, a BCL-2 inhibitor used to treat certain hematological cancers, exhibits low oral bioavailability and high interpatient pharmacokinetic variability. Venetoclax is commonly administered with prophylactic antifungal drugs that may result in drug interactions, of which the underlying mechani...